Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExoGiov is an extracellular vesicle (EV)-based product developed by Ambiotech using its proprietary Bio-Pulsed technology. The active ingredient consists of bio-pulsed exosomes derived from Specific Pathogen Free (SPF) chicken embryonic mesenchymal stem cells. The product is indicated for multiple cosmetic and aesthetic applications, including hair loss (alopecia), skin aging, and wound healing. The Bio-Pulsed technology enhances exosome production and potency, increasing protein and miRNA content compared to conventional methods. ExoGiov works by promoting tissue repair and regeneration through extracellular vesicle-mediated signaling, delivering growth factors and anti-inflammatory agents that stimulate the expression of Type I collagen, Type III collagen, and elastin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ExoGiov.